The Prognostic Value of Serum Sialic Acid in Patients with Nasopharyngeal Carcinoma: A Propensity Score Matching Study

References

• Wong KCW, Hui EP, Lo KW, et al. Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol. 2021;18(11):679–695. doi:10.1038/s41571-021-00524-x
   PubMed Web of Science ®Google Scholar
• Chen Y, Chan ATC, Le Q, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80. doi:10.1016/S0140-6736(19)30956-0
   PubMed Web of Science ®Google Scholar
• Al-Anazi AE, Alanazi BS, Alshanbari HM, et al. Increased prevalence of EBV infection in nasopharyngeal carcinoma patients: a Six-Year Cross-Sectional study. Cancers. 2023;15(3):643. doi:10.3390/cancers15030643
   PubMed Web of Science ®Google Scholar
• Young LS, Dawson CW. Epstein-Barr virus and nasopharyngeal carcinoma. Chin J Cancer. 2014;33(12):581–590. doi:10.5732/cjc.014.10197
   PubMedGoogle Scholar
• Bei J, Zuo X, Liu W, Guo Y, Zeng Y. Genetic susceptibility to the endemic form of NPC. Chin Clin Oncol. 2016;5(2):15. doi:10.21037/cco.2016.03.11
   PubMed Web of Science ®Google Scholar
• Cui Q, Feng QS, Mo HY, et al. An extended genome-wide association study identifies novel susceptibility loci for nasopharyngeal carcinoma. Hum Mol Genet. 2016;25(16):3626–3634. doi:10.1093/hmg/ddw200
   PubMed Web of Science ®Google Scholar
• Xu T, Zhou X, Shen C, Hu C. Suggestions for surveillance and radiation strategy in nasopharyngeal carcinoma treated with IMRT: based on hazard-rate and patterns of recurrence. Oral Oncol. 2018;76:61–67. doi:10.1016/j.oraloncology.2017.11.022
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen L, Hu G, et al. Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized Phase III trial. J Clin Oncol. 2022;40(22):2420–2425. doi:10.1200/JCO.22.00327
   PubMed Web of Science ®Google Scholar
• Qiang M, Li C, Sun Y, et al. A prognostic predictive system based on deep learning for locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2021;113(5):606–615. doi:10.1093/jnci/djaa149
   PubMedGoogle Scholar
• Wang G, Dong Z, Huang C, et al. The value of integrating tumor volume and plasma Epstein-Barr virus DNA load during sequential chemoradiotherapy for prognostic prediction and therapeutic guidance in high-risk locoregionally advanced nasopharyngeal carcinoma. Oral Oncol. 2023;145:106500. doi:10.1016/j.oraloncology.2023.106500
   PubMed Web of Science ®Google Scholar
• Feng Y, Cao C, Hu Q, Chen X. Prognostic value and staging classification of lymph nodal necrosis in nasopharyngeal carcinoma after Intensity-Modulated radiotherapy. Cancer Res Treat. 2019;51(3):1222–1230. doi:10.4143/crt.2018.595
   PubMed Web of Science ®Google Scholar
• Li XH, Chang H, Xu BQ, et al. An inflammatory biomarker-based nomogram to predict prognosis of patients with nasopharyngeal carcinoma: an analysis of a prospective study. Cancer Med. 2017;6(1):310–319. doi:10.1002/cam4.947
   PubMed Web of Science ®Google Scholar
• Sawhney H, Kumar CA. Correlation of serum biomarkers (TSA & LSA) and epithelial dysplasia in early diagnosis of oral precancer and oral cancer. Cancer Biomark. 2012;10(1):43–49. doi:10.3233/CBM-2012-0226
   Web of Science ®Google Scholar
• Berghuis AY, Pijnenborg JFA, Boltje TJ, Pijnenborg JMA. Sialic acids in gynecological cancer development and progression: impact on diagnosis and treatment. Int J Cancer. 2022;150(4):678–687. doi:10.1002/ijc.33866
   PubMed Web of Science ®Google Scholar
• Gao C, Fan Z, Yang J, Shi M, Li Y, Zhan H. Diagnostic role and prognostic value of tumor markers in high-grade gastro-enteropancreatic neuroendocrine neoplasms. Pancreatology. 2023;23(2):204–212. doi:10.1016/j.pan.2023.01.009
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi:10.1158/1078-0432.CCR-04-0713
   PubMed Web of Science ®Google Scholar
• Dharmadhikari G, Stolz K, Hauke M, et al. Siglec-7 restores β-cell function and survival and reduces inflammation in pancreatic islets from patients with diabetes. Sci Rep-Uk. 2017;7(1). doi:10.1038/srep45319
   PubMedGoogle Scholar
• Cheeseman J, Kuhnle G, Spencer DIR, Osborn HMI. Assays for the identification and quantification of sialic acids: challenges, opportunities and future perspectives. Bioorg Med Chem. 2021;30:115882. doi:10.1016/j.bmc.2020.115882
   PubMed Web of Science ®Google Scholar
• Xia L, Oyang L, Lin J, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20(1). doi:10.1186/s12943-021-01316-8
   Web of Science ®Google Scholar
• Sun L, Zhang H, Gao P. Metabolic reprogramming and epigenetic modifications on the path to cancer. Protein Cell. 2022;13(12):877–919. doi:10.1007/s13238-021-00846-7
   PubMed Web of Science ®Google Scholar
• Sun H, Zhou Y, Skaro MF, et al. Metabolic reprogramming in cancer is induced to increase proton production. Cancer Res. 2020;80(5):1143–1155. doi:10.1158/0008-5472.CAN-19-3392
   PubMed Web of Science ®Google Scholar
• Visser EA, Moons SJ, Timmermans SBPE, de Jong H, Boltje TJ, Büll C. Sialic acid O-acetylation: from biosynthesis to roles in health and disease. J Biol Chem. 2021;297(2):100906. doi:10.1016/j.jbc.2021.100906
   PubMed Web of Science ®Google Scholar
• Schutter EM, Visser JJ, van Kamp GJ, et al. The utility of lipid-associated sialic acid (LASA or LSA) as a serum marker for malignancy. A review of the literature. Tumour Biol. 1992;13(3):121–132. doi:10.1159/000217755
   PubMedGoogle Scholar
• Läubli H, Nalle SC, Maslyar D. Targeting the siglec–sialic acid immune axis in cancer: current and future approaches. Cancer Immunol Res. 2022;10(12):1423–1432. doi:10.1158/2326-6066.CIR-22-0366
   PubMed Web of Science ®Google Scholar
• Stefenelli N, Klotz H, Engel A, Bauer P. Serum sialic acid in malignant tumors, bacterial infections, and chronic liver diseases. J Cancer Res Clin Oncol. 1985;109(1):55–59. doi:10.1007/BF01884255
   PubMed Web of Science ®Google Scholar
• Elgohary MM, Helmy MW, Abdelfattah EA, et al. Targeting sialic acid residues on lung cancer cells by inhalable boronic acid-decorated albumin nanocomposites for combined chemo/herbal therapy. J Control Release. 2018;285:230–243. doi:10.1016/j.jconrel.2018.07.014
   PubMed Web of Science ®Google Scholar
• Basoglu M, Atamanalp SS, Yildirgan MI, et al. Correlation between the serum values of soluble intercellular adhesion molecule-1 and total sialic acid levels in patients with breast cancer. Eur Surg Res. 2007;39(3):136–140. doi:10.1159/000100110
   PubMed Web of Science ®Google Scholar
• Tarantino P, Carmagnani Pestana R, Corti C, et al. Antibody–drug conjugates: smart chemotherapy delivery across tumor histologies. Ca a Cancer J Clinicians. 2022;72(2):165–182. doi:10.3322/caac.21705
   PubMed Web of Science ®Google Scholar
• Büll C, Boltje TJ, Balneger N, et al. Sialic acid blockade suppresses tumor growth by enhancing t-cell–mediated tumor immunity. Cancer Res. 2018;78(13):3574–3588. doi:10.1158/0008-5472.CAN-17-3376
   PubMed Web of Science ®Google Scholar
• Li C, Qiu Q, Gao X, et al. Sialic acid conjugate-modified liposomal platform modulates immunosuppressive tumor microenvironment in multiple ways for improved immune checkpoint blockade therapy. J Control Release. 2021;337:393–406. doi:10.1016/j.jconrel.2021.06.027
   PubMed Web of Science ®Google Scholar
• Gray MA, Stanczak MA, Mantuano NR, et al. Targeted glycan degradation potentiates the anticancer immune response in vivo. Nat Chem Biol. 2020;16(12):1376–1384. doi:10.1038/s41589-020-0622-x
   PubMed Web of Science ®Google Scholar